Fragment 176-191, CJC-1295, and ipamorelin blend research: what each peptide does, how they differ, dosing logic, storage, and safety caveats.
A fragment 176-191, CJC-1295, and ipamorelin blend is a research peptide vial that combines a growth hormone fragment studied for fat metabolism with two secretagogues that trigger growth hormone release. In preclinical work, CJC-1295 supplies a GHRH signal, ipamorelin supplies a ghrelin-receptor signal, and fragment 176-191 is tracked separately for lipolytic endpoints. None of the three peptides is FDA-approved for human use, so the blend is sold and handled as a laboratory reference material only.
Some catalogs list the identical product as fragment 176 191 & cjc 1295 & ipamorelin blend, and the naming difference is purely cosmetic. Both refer to one lyophilized vial containing all three peptides.
What Is Inside a Fragment 176-191 & CJC-1295 & Ipamorelin Blend?
Most suppliers formulate the blend with equal milligram amounts of each peptide, such as 2 mg per component, in a single vial. The three molecules were chosen because they act on different targets instead of duplicating one pathway.
- Fragment 176-191: the C-terminal 16 amino acids of human growth hormone, used in research on lipolysis and fat oxidation.
- CJC-1295: a growth hormone-releasing hormone analog. The DAC form carries a linker that binds albumin and stretches its half-life, while the no-DAC form behaves like modified GRF(1-29).
- Ipamorelin: a five-amino-acid ghrelin-receptor agonist that releases growth hormone with comparatively little effect on cortisol, prolactin, or appetite in animal studies.
Purity grade matters more than the label. A blend below 98% purity, or one carrying residual trifluoroacetate, can produce results that have nothing to do with the peptides themselves.
How Each Component Works
Fragment 176-191
Fragment 176-191 does not meaningfully bind the growth hormone receptor or the GHRH receptor. Rodent studies suggest it influences fat breakdown and limits fat storage without raising IGF-1 or disturbing blood glucose. Human data are thin, and the related compound AOD9604 failed to produce meaningful weight loss in its own clinical trials.
CJC-1295
CJC-1295 binds GHRH receptors on pituitary somatotroph cells and prompts them to release growth hormone. The DAC version stays active in circulation for roughly six to eight days, which is why it is studied for sustained IGF-1 elevation rather than a sharp pulse. The no-DAC version clears within minutes and is used when researchers want a cleaner pulse.
Ipamorelin
Ipamorelin activates the ghrelin receptor GHS-R1a and produces a growth hormone pulse with a reported half-life of about two hours. Selectivity is its main research draw: in animal models it raises growth hormone with far less cortisol and prolactin response than older ghrelin mimetics.
How the Three Components Compare
| Component | Receptor target | Reported half-life | Main research focus |
|---|---|---|---|
| Fragment 176-191 | No pituitary receptor; acts on adipose tissue signaling | Minutes in circulation | Lipolysis and fat oxidation |
| CJC-1295 with DAC | GHRH receptor | About 6-8 days | Sustained growth hormone and IGF-1 elevation |
| CJC-1295 without DAC | GHRH receptor | Minutes | Pulsatile growth hormone release |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | About 2 hours | Selective growth hormone pulse |
The table is the fastest way to see why the blend is not a single mechanism. Only CJC-1295 and ipamorelin act on the pituitary, and only fragment 176-191 is studied for direct fat-tissue effects.
Researchers weighing cjc-1295 ipamorelin vs tesamorelin usually focus on the fact that tesamorelin is an FDA-approved GHRH analog for a specific clinical population, while CJC-1295 and ipamorelin remain unapproved research peptides.
Why These Three Are Studied Together
GHRH analogs and ghrelin-receptor agonists work through separate signaling cascades, and combining them produces a larger growth hormone pulse than either alone in study models. Adding fragment 176-191 lets one protocol track a pituitary endpoint and a fat-metabolism endpoint at the same time.
That convenience is also the source of most online confusion. Anyone searching what is cjc-1295 ipamorelin used for will find a mix of legitimate research summaries and marketing claims, and the two are not the same thing. The blend is a lab tool, not a proven therapy.
Dosing, Timing, and Frequency Questions
No single established protocol exists for the blend. Published work uses different ratios, schedules, and endpoints, and nearly all of it is preclinical.
Questions such as how often do you inject cjc-1295 ipamorelin and the best time to take cjc 1295 ipamorelin come from bodybuilding forums rather than from the literature. Researchers who do apply timing logic usually align administration with natural growth hormone pulses, which peak during deep sleep and rise after fasting.
Anyone considering personal use should talk with a healthcare professional first. Self-dosing an unapproved blend carries risks that no forum protocol can offset.
Storage, Reconstitution, and Handling
- Store lyophilized vials at -20°C or colder, protected from light.
- Reconstitute with bacteriostatic water, directing the stream down the vial wall instead of onto the powder.
- Keep reconstituted vials at 2-8°C and use them within a few weeks.
- Avoid repeated freeze-thaw cycles, which degrade peptides quickly.
- Swirl gently to dissolve; never shake a peptide solution.
A blend is more fragile than a single peptide because each component has its own stability profile. Fragment 176-191, CJC-1295, and ipamorelin degrade at different rates, so a solution that looks clear may already be losing potency.
Safety, Sourcing, and Legal Status
Fragment 176-191, CJC-1295, and ipamorelin are not FDA-approved for human use in the United States. They are sold as research chemicals, which means no regulator verifies their identity, purity, or sterility before they reach a buyer.
Anecdotal reports describe injection-site irritation, water retention, joint discomfort, and numbness or tingling. Growth hormone elevation also raises IGF-1, and IGF-1 has theoretical ties to tumor growth, which makes a personal or family history of cancer a serious reason to avoid these compounds entirely.
Claims about cjc 1295 ipamorelin muscle growth are largely extrapolated from growth hormone physiology rather than from controlled human trials of the blend itself. Testimonials and before-and-after photos are not evidence.
The Short Answer
A fragment 176-191, CJC-1295, and ipamorelin blend is a three-peptide research combination that pairs a lipolytic growth hormone fragment with two growth hormone secretagogues. It is studied for pituitary output and fat metabolism, it is not approved for human use, and every therapeutic claim attached to it remains unproven.
If you are researching the blend for a lab protocol, buy only from suppliers that publish third-party certificates of analysis for each lot, and follow the storage rules above. If you are considering it for personal use, consult a licensed healthcare professional before doing anything else.
RELATED PEPTIDE TOPICCJC-1295 peptideFrequently Asked Questions
Is the fragment 176-191, CJC-1295, and ipamorelin blend FDA-approved?
No. None of the three peptides in the blend is FDA-approved for human use in the United States, and they are legally sold only as research chemicals. Tesamorelin is the one FDA-approved GHRH analog in this family, and it is cleared for a specific diagnosed condition rather than general use.
What is the fragment 176-191, CJC-1295, and ipamorelin blend studied for?
Research interest centers on two endpoints: growth hormone and IGF-1 output driven by CJC-1295 and ipamorelin, and fat metabolism driven by fragment 176-191. CJC-1295 acts on GHRH receptors, ipamorelin acts on the ghrelin receptor, and fragment 176-191 is examined separately for lipolytic activity. Almost all of this work is preclinical.
How should the fragment 176-191, CJC-1295, and ipamorelin blend be stored?
Keep lyophilized vials frozen at -20°C or colder, away from light. After reconstitution with bacteriostatic water, store the vial at 2-8°C and use it within a few weeks. Repeated freeze-thaw cycles and vigorous shaking both degrade the peptides and should be avoided.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.